{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"description":"Severe non-hematologic adverse events were defined as adverse events grade 4 (life threatening or disabling) or grade 5 (death), regardless of attribution to study drug. Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria (CTC) version 2.","groups":[{"id":"OG000","title":"Anakinra With/Without Dexamethasone"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Duration of treatment (up to 5 years)","title":"Number of Patients With Severe Non-hematological Adverse Events in Patients Receiving Anakinra Alone or in Combination With Dexamethasone.","type":"SECONDARY","unitOfMeasure":"participants"}